A groundbreaking artificial intelligence (AI) test has been developed to identify which men with high-risk, non-metastatic prostate cancer are most likely to benefit from the drug abiraterone. This advancement, presented at the American Society of Clinical Oncology’s annual meeting, could revolutionize treatment strategies by ensuring…